✦ LIBER ✦

Sponsorship and design characteristics of trials registered in ClinicalTrials.gov

✍ Scribed by Roumiantseva, Dina; Carini, Simona; Sim, Ida; Wagner, Todd H.

Book ID: 122222348
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 396 KB
Volume: 34
Category: Article
ISSN: 1551-7144
DOI: 10.1016/j.cct.2013.01.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characteristics of Clinical Trials Regis

Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010

✍ Califf, R. M.; Zarin, D. A.; Kramer, J. M.; Sherman, R. E.; Aberle, L. H.; Tasne 📂 Article 📅 2012 🏛 American Medical Association 🌐 English ⚖ 124 KB

Characteristics of pediatric cardiovascu

Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov

✍ Hill, Kevin D.; Chiswell, Karen; Califf, Robert M.; Pearson, Gail; Li, Jennifer 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 823 KB

Characteristics of antimicrobial studies

Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov

✍ Stockmann, Chris; Sherwin, Catherine M.T.; Ampofo, Krow; Hersh, Adam L.; Pavia, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 590 KB

The use of patient-reported outcomes ins

The use of patient-reported outcomes instruments in registered clinical trials: Evidence from ClinicalTrials.gov

✍ John F. Scoggins; Donald L. Patrick 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 227 KB

CLINICAL TRIALS IN PERIPHERAL VASCULAR D

CLINICAL TRIALS IN PERIPHERAL VASCULAR DISEASE: PIPELINE AND TRIAL DESIGNS_AN EVALUATION OF THE CLINICALTRIALS.GOV DATABASE

✍ Subherwal, Sumeet; Patel, Manesh; Chiswell, Karen; Jones, William; Conte, Michae 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Drug delivery trends in clinical trials

Drug delivery trends in clinical trials and translational medicine: Updated analysis of ClinicalTrials.gov database

✍ Rodney J.Y. Ho; Jenny Y. Chien 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

While the number of clinical trials has continued to grow by about 20% in the past six months, no corresponding growth in product approval by the food and drug administration is seen or anticipated in the near future. Late-stage clinical failures due to lack of efficacy or toxicity continues to be a